Kenneth K Mugwanya
Overview
Explore the profile of Kenneth K Mugwanya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar R, Rao D, Sharma A, Phiri J, Zimba M, Phiri M, et al.
BMJ Open
. 2024 Sep;
14(9):e080218.
PMID: 39242170
Introduction: Women engaging in sex work (WESW) have 21 times the risk of HIV acquisition compared with the general population. However, accessing HIV pre-exposure prophylaxis (PrEP) remains challenging, and PrEP...
2.
Wu L, Niu X, Brunelli M, Mugwanya K
Curr HIV/AIDS Rep
. 2024 Aug;
21(5):264-281.
PMID: 39120667
Purpose Of Review: Adherence-concentration-efficacy benchmarks have not been fully characterized for cisgender women using emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) oral daily pre-exposure prophylaxis (PrEP) for HIV prevention. Recent Findings: We conducted...
3.
Zewdie K, Muwonge T, Ssebuliba T, Bambia F, Nampewo O, Stein G, et al.
AIDS
. 2024 Aug;
38(14):1965-1971.
PMID: 39088310
Objectives: We evaluated a recently developed and validated point-of-care urine tenofovir (POC TFV) test to determine whether its use improves the accuracy of self-reported adherence to preexposure prophylaxis (PrEP) and...
4.
Tseng A, Mugwanya K, Szpiro A, van Heerden A, Ntinga X, Schaafsma T, et al.
J Acquir Immune Defic Syndr
. 2024 Jun;
96(4):318-325.
PMID: 38916425
Background: People living with HIV require reliable access to and adequate supply of antiretroviral therapy (ART) for viral suppression. The Deliver Health Study, a randomized trial conducted during the COVID-19...
5.
Wu L, Saina M, Brown C, Chege D, Donnell D, Glidden D, et al.
Front Reprod Health
. 2024 Jun;
6:1325257.
PMID: 38860025
Background: Oral pre-exposure prophylaxis (PrEP) using co-formulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) is a potent HIV prevention method for men and women, with its efficacy highly dependent on...
6.
Zewdie K, Ngure K, Mwangi M, Mwangi D, Maina S, Etyang L, et al.
J Int AIDS Soc
. 2024 Mar;
27(3):e26222.
PMID: 38446643
Introduction: Delivery of oral pre-exposure prophylaxis (PrEP) is being scaled up in Africa, but clinic-level barriers including lengthy clinic visits may threaten client continuation on PrEP. Methods: Between January 2020...
7.
Zewdie K, Kiweewa F, Ssebuliba T, Morrison S, Muwonge T, Boyer J, et al.
Front Reprod Health
. 2024 Jan;
5:1240990.
PMID: 38260049
Introduction: Oral pre-exposure prophylaxis (PrEP) is recommended during pregnancy for at-risk cisgender women. Pregnancy is known to impede bone growth and tenofovir-based PrEP may also yield detrimental changes to bone...
8.
Mugwanya K, Palayew A, Schaafsma T, Irungu E, Bukusi E, Mugo N, et al.
J Int AIDS Soc
. 2023 Jul;
26(7):e26137.
PMID: 37403405
Introduction: Effective PrEP use is critical for impact, but data are limited on common patterns of continuation and coverage among persons using PrEP in real-world settings. Methods: Data are from...
9.
Velloza J, Roche S, Owidi E, Irungu E, Dollah A, Kwach B, et al.
J Int AIDS Soc
. 2023 Feb;
26(2):e26055.
PMID: 36739603
Introduction: HIV pre-exposure prophylaxis (PrEP) is an essential prevention strategy being scaled up for priority populations in Kenya, including for HIV serodiscordant couples. The COVID-19 pandemic posed challenges to PrEP...
10.
Mugwanya K, Kinuthia J
Front Reprod Health
. 2022 Oct;
3:683415.
PMID: 36304007
Sexually active African women are a priority population for HIV prevention due to the disproportionately high frequency of new HIV infections. Family planning (FP) clinics offer an already trusted platform...